BNET Industries

Market Cap:$146.6B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
News & Analysis
Filter by
litigation and pfizer inc. - All News and Analysis
Pfizer Tries Again for Sanctions Against Neurontin Witness
Pfizer PFE is playing hardball in its attempt to get sanctions applied to an expert in the Neurontin litigation who contacted another witness wthout the drug company's permission. The company is asking a judge to overturn the ruling of a federal magistrate that sanctions should not be applied to Dr....
Law & Order: The Pfizer Episode! "Doped" Sketches the Kopchinski-Bextra Settlement
Chung-chung! NBC on Friday night aired an episode of Law & Order that appears to have been inspired in part by Pfizer's $2.3 billion Bextra settlement. I'm not the only one who noticed the "ripped from the headlines" quality of "Doped," the eighth episode of season 20. CafePharma is already...
Grassley's NAMI Probe May Want to Look at Pfizer Whistleblower Suit
Sen. Charles Grassley is investigating the National Alliance for the Mentally Ill, the New York Times reports. He might want to look into Pfizer's $2.3 billion Bextra settlement as one of the suits within it made some juicy claims about how NAMI works. by Jim Edwards
DOJ Blames Pfizer Management for Bextra Mess: "The Goal Was to Avoid Getting Caught"
The Department of Justice blamed Pfizer's management for the $2.3 billion Bextra settlement by creating a "corporate culture" in which off-label promotion was encouraged, and where not going along was regarded as a "CLM" or career-limiting move. by Jim Edwards
Pfizer's "Witness Tampering" Motion in Neurontin Case Is Denied
A federal judge has ruled against Pfizer's request for sanctions against a witness in the Neurontin litigation whom it alleged had attempted to wrongly influence another witness in the case. The judge dismissed Pfizer's allegations with just four words: This Motion is DENIED. by Jim Edwards
List of Pfizer's Trovan Victims Has Been Lost, Nigerian Officials Say
Nigerian officials have lost the list of victims to be compensated under Pfizer's $75 million settlement with the Kano State government following the Trovan meningitis trials in that country. The money was to be paid by Oct. 15, but the process has now been stretched out a further three months...
Pfizer Email on "Negligible Evidence" for Neurontin as a Bipolar Drug Is Focus of Lawyers' Tug-of-War
An email in the Neurontin litigation that Pfizer claims should be sealed shows former Pfizer vp/neuroscience Atul Pande telling a colleague that there is "negligible evidence" for the use of Neurontin in bipolar disorder and that the drug is "not a good anti-manic treatment." by Jim Edwards
Pfizer Accused of "Blatant Hypocrisy" Over Alleged Witness Tampering in Neurontin Case
Plaintiffs in the Neurontin litigation have accused Pfizer of "blatant hypocrisy" for insisting that witnesses should not contact each other in the case because Pfizer once sent an ex-CIA agent to the home of a witness in a separate Neurontin case. by Jim Edwards
Pfizer's Lawyers Play Musical Chairs in Wake of Bextra Settlement
Pfizer's lawyers have found themselves playing musical chairs since the $2.3 billion Bextra settlement. The general counsel's office has been stripped of part of its compliance role under a new corporate integrity agreement with the government stemming from the Bextra scandal. More recently, senior corporate counsel Paulette Morgan left Pfizer...
2 Can Play That Game: Pfizer Claims Witness-Tampering in Neurontin Case
Pfizer can play hardball too. A few weeks after sustaining a black eye in the Neurontin litigation when it sent an ex-CIA agent to the home of a plaintiffs' witness, Pfizer has accused the plaintiffs' side of doing something similar: an expert witness for the family of a man who...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes

